Recombinant quadrivalent influenza vaccine (RIV4) and standard egg-based quadrivalent inactivated IV (IIV4) show comparable effectiveness in reducing influenza-related hospitalization among older ...
The quadrivalent recombinant influenza vaccine (RIV4) demonstrated non-inferior immune responses in children and adolescents aged 9-17 years compared with adults aged 18-49 years, with the safety ...
More than 80% of immunosuppressed patients with idiopathic inflammatory myopathy achieved seroconversion after receiving the ...
The vaccine was a live zoster vaccine, meaning it contained a weakened form of the varicella zoster virus that causes shingles. In many countries, this type of vaccine is now being replaced with a non ...
LYON, France--(BUSINESS WIRE)--BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission ...
A recombinant protein is a protein made by genetically engineered cells rather than extracted directly from its natural source. Scientists insert the gene for the desired protein into a production ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results